GAITHERSBURG, Md., Feb. 6, 2017 /PRNewswire/ -- Altimmune, Inc., a clinical stage immunotherapeutics company targeting infectious diseases, announced today that Chief Executive Officer Bill Enright will present at the BIO CEO & Investor Conference on Monday, February 13, 2017 at 4:00 PM ET. The conference will be held at the Waldorf Astoria New York.
About Altimmune, Inc.
Altimmune is a clinical stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system. The Company's most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications.
On January 19, 2017, the Company announced the signing of a definitive agreement to merge with PharmAthene, Inc. (NYSE MKT: PIP) in an all-stock transaction. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/altimmune-to-present-at-the-bio-ceo--investor-conference-300402161.html
SOURCE Altimmune, Inc.